The purchase price for the transaction was $308m.
AndersonBrecon is specialises in pharmaceutical contract packaging business.
The results of operations of AndersonBrecon are reported within discontinued operations.
AmerisourceBergen said the completion of the divestiture has no impact on the firm’s financial performance expectations for fiscal 2013, which were updated on 25 April.
Source:
http://www.packagingnews.co.uk/news/andersonbrecon-deal-formalised/
